Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-21EMA Authorised: Liprolog (insulin lispro) — Eli Lilly Nederland B.V.
EMA authorised Liprolog (insulin lispro) for diabetes mellitus. The marketing authorisation holder is Eli Lilly Nederland B.V.; decision dat…
-
EMA approval · 2026-01-21EMA Authorised: Humalog (insulin lispro) — Eli Lilly Nederland B.V.
The European Medicines Agency authorised Humalog (insulin lispro) for the treatment of diabetes mellitus. The marketing authorisation holder…
-
EMA approval · 2026-01-21EMA Authorised: Abasaglar (previously Abasria) (insulin glargine) — Eli Lilly Nederland B.V.
EMA authorized Abasaglar, a biosimilar insulin glargine, for diabetes mellitus. The marketing authorization holder is Eli Lilly Nederland B.…
-
EMA approval · 2025-11-17EMA Authorised: Awiqli (insulin icodec) — Novo Nordisk A/S
EMA authorised Awiqli (insulin icodec) from Novo Nordisk A/S for the treatment of diabetes, including type 2 diabetes.
-
EMA approval · 2025-09-17EMA Authorised: Ogluo (Glucagon) — Strongbridge Dublin Limited
EMA has authorised Ogluo, a glucagon medicine from Strongbridge Dublin Limited, for use in diabetes mellitus. The product is approved for em…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA approval · 2025-09-15EMA Authorised: Baqsimi (Glucagon) — Amphastar France Pharmaceuticals
EMA authorised Baqsimi, an intranasal glucagon product, for emergency treatment of severe hypoglycemia in people with diabetes, marketed by …
-
FDA approval · 2025-09-15FDA Approved: GLUCAGON — Original Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s original application for a generic glucagon product, enabling its marketing to treat severe hypoglycemia i…
-
FDA approval · 2025-07-30FDA Approved: GLUCAGON — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA has approved a supplemental application for glucagon submitted by Fresenius Kabi USA, LLC. The approval finalizes changes proposed i…
-
FDA approval · 2025-07-22FDA Approved: GLUCAGON — Original Application (Lupin Pharmaceuticals, Inc.)
FDA approved Lupin Pharmaceuticals' generic glucagon injection under an Original Application (ANDA214457). The approval enables Lupin to mar…
-
EMA approval · 2025-06-27EMA Authorised: Tresiba (insulin degludec) — Novo Nordisk A/S
The EMA authorised Tresiba (insulin degludec) for use in diabetes mellitus in the European Union. Novo Nordisk A/S is the marketing authoriz…
-
EMA approval · 2025-05-28EMA Authorised: NovoRapid (insulin aspart) — Novo Nordisk A/S
EMA authorised NovoRapid (insulin aspart) for the treatment of diabetes mellitus; decision date 28 May 2025.
-
FDA approval · 2025-05-07FDA Approved: HUMALOG KWIKPEN — Supplemental Application (Eli Lilly and Company)
FDA approved a supplemental application for HUMALOG KWIKPEN (insulin lispro) from Eli Lilly and Company.
-
FDA approval · 2025-03-17FDA Approved: BAQSIMI — Supplemental Application (Amphastar Pharmaceuticals, Inc.)
The FDA approved a supplemental application for BAQSIMI (glucagon) from Amphastar Pharmaceuticals, Inc., the nasal glucagon product for emer…
-
FDA approval · 2025-03-14FDA Approved: GVOKE HYPOPEN 0.5 MG AUTO-INJECTOR — Supplemental Application (Xeris Pharmaceuticals, Inc.)
FDA approved a supplemental application to add the GVOKE HYPOPEN 0.5 mg auto-injector as a new administration form for glucagon injection so…
-
FDA approval · 2025-03-07FDA Approved: MYXREDLIN — Supplemental Application (Baxter Healthcare Corporation)
FDA approved a supplemental application for MYXREDLIN (insulin human) from Baxter Healthcare Corporation.
-
EMA approval · 2025-03-04EMA Authorised: Ryzodeg (insulin aspart;insulin degludec) — Novo Nordisk A/S
The European Medicines Agency authorised Ryzodeg (insulin aspart and insulin degludec) from Novo Nordisk A/S for diabetes mellitus.
-
FDA approval · 2025-02-14FDA Approved: MERILOG — Original Application (Sanofi-Aventis U.S. LLC)
FDA approves Merilog (insulin aspart-SZJJ) under an original biologics license application by Sanofi-Aventis U.S. LLC.
-
FDA approval · 2024-12-12FDA Approved: GLUCAGON — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's original application for a generic glucagon injectable product.
-
EMA approval · 2024-11-29EMA Authorised: Duloxetine Zentiva (duloxetine) — Zentiva, k.s.
The EMA authorised Duloxetine Zentiva (duloxetine) from Zentiva, k.s. as an approved medicinal product for neuralgia/diabetic neuropathy, ma…
-
FDA approval · 2024-08-09FDA Approved: REZVOGLAR KWIKPEN — Supplemental Application (Eli Lilly and Company)
The FDA approved a supplemental application for Rezvoglar KwikPen (insulin glargine-AGLR) from Eli Lilly and Company.
-
EMA approval · 2024-02-02EMA Authorised: Actraphane (Insulin human) — Novo Nordisk A/S
Actraphane (insulin human) has been authorised in the EU for the treatment of diabetes mellitus.
-
EMA approval · 2024-01-24EMA Authorised: Mixtard (Insulin human) — Novo Nordisk A/S
Mixtard (insulin human) by Novo Nordisk A/S has been authorised for use in the EU for diabetes mellitus.
-
FDA approval · 2023-12-22FDA Approved: GVOKE HYPOPEN 0.5 MG AUTO-INJECTOR — Supplemental Application (Xeris Pharmaceuticals, Inc.)
The FDA approved a supplemental application to add the Gvoke Hypopen 0.5 mg auto-injector for glucagon injection solution. This expands the …
-
EMA approval · 2023-12-06EMA Authorised: Amglidia (glibenclamide) — Ammtek
Amglidia (glibenclamide) has been authorised in the EU for diabetes mellitus as an orphan medicine.
-
FDA approval · 2023-08-31FDA Approved: ADMELOG — Supplemental Application (Sanofi-Aventis U.S. LLC)
FDA granted approval of a supplemental application for ADMELOG (insulin lispro) from Sanofi-Aventis U.S. LLC.